Glaukos Corp

NYSE:GKOSUnited States

Oct 16, 2024

Show headlines and story abstract

• Glaukos Reports Positive Results From Potential Eye Disease Treatment Study, from 5:36PM ET on Wednesday Oct 16, 2024 by MT Newswires

  5:36PM ET on Wednesday Oct 16, 2024 by MT Newswires
  Companies Mentioned: GKOS
  05:36 PM EDT, 10/16/2024 (MT Newswires) -- Glaukos (GKOS) on Wednesday announced positive topline results from its phase 3 confirmatory trial for Epioxa, a corneal cross-linking treatment for keratoconus, a rare corneal disorder. The trial achieved ...

• Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa(TM), Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety, from 4:05PM ET on Wednesday Oct 16, 2024 by Dow Jones

  4:05PM ET on Wednesday Oct 16, 2024 by Dow Jones
  Companies Mentioned: GKOS
  
  Exchange Commission (SEC) on August 2, 2024. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.